Hey readers! Here's something you don't hear every day: the same signaling molecule your body uses to keep its immune cells in check is now being borrowed as a therapy. This week we dig into low-dose IL-2 and the broader wave of immune-modulating approaches aimed at protecting insulin-producing cells after a T1D diagnosis. Let's get into it.
🧬 The headline: low-dose IL-2 and Tregs
IL-2 and immunoregulatory therapies in newly diagnosed type 1 diabetes lays out the logic behind using low-dose interleukin-2 (IL-2) to calm the autoimmune attack in freshly diagnosed T1D, as evaluated in the phase 2b DIABIL-2 trial. - The Lancet Diabetes & Endocrinology
The reasoning is worth understanding, because it reframes the goal. T1D doesn't flip on overnight; it moves through stages, from autoantibody positivity to progressive loss of insulin secretion after diagnosis. That staging is exactly why there's a window to intervene and try to slow the loss.
Why IL-2 specifically? The article centers the mechanism on regulatory T cells (Tregs), the immune cells whose job is to keep other immune cells from overreacting.
regulatory T cells (Tregs) are highly sensitive to IL-2, which is necessary for optimal Treg maintenance and function.
The idea behind a low dose is to nudge Tregs without broadly revving up the immune system. IL-2 touches multiple lymphocyte populations, so dosing precision matters, and that is a big part of what a controlled trial like DIABIL-2 is built to sort out. The abstract frames the rationale rather than reporting a finished verdict, so treat this as the scientific case for the approach, not a final scorecard.
If you want the one-sentence takeaway: instead of attacking the immune system, this strategy tries to restore its own braking mechanism. That is a meaningfully different philosophy from insulin replacement, and it's the thread connecting several stories below.
💉 Disease-modifying therapy is moving into clinics
The IL-2 rationale doesn't exist in a vacuum. The most concrete arrival this fall is teplizumab.
Lurie Children's Offers First Disease-Modifying Therapy for Newly Diagnosed Type 1 Diabetes Patients reports that the Chicago hospital is now providing Tzield (teplizumab-mzwv), following the FDA's expanded approval for stage 3 disease. - Lurie Children's
Tzield is now available there for patients ages 8 to 17 diagnosed within the past 8 weeks who still have evidence of remaining insulin production, delivered as two 12-day outpatient IV infusion courses six months apart. The hospital is careful to say it slows progression and preserves remaining insulin, but does not cure the disease.
"This is an important milestone for families facing a new diagnosis of type 1 diabetes," said Naomi Fogel, MD, Director of the Diabetes Program at Lurie Children's.
The practical note that stands out: being able to offer this in-house, rather than routing families elsewhere, is itself part of making immunotherapy real for patients.
Type 1 Diabetes Immunotherapy: Can ATG Rival Teplizumab? covers TrialNet's new ASCEND T1D head-to-head study, comparing low-dose anti-thymocyte globulin (ATG) against teplizumab in people with Stage 2 disease. - Diabetes in Control
ASCEND T1D plans to enroll 60 participants ages 4 to 34, with everyone receiving active therapy: 40 get low-dose ATG and 20 get teplizumab. The logistics differ sharply, which matters for real lives.
Participants assigned to ATG receive two infusions over two to three days. In contrast, those receiving teplizumab undergo 14 daily infusions over two weeks.
It isn't built as a definitive superiority contest; early results are meant to clarify whether a larger ATG extension study is justified. The deeper point ties right back to the IL-2 story: comparing a broad immune agent (ATG) and a targeted one (anti-CD3 teplizumab) helps researchers learn whether different immune pathways can reach similar benefits. More than one effective option means more treatment choice.
🔬 New candidates and the immune cells behind T1D
The pipeline aimed at the immune system keeps widening.
Zag Bio Advances ZAG-101 into Clinical Development for Type 1 Diabetes describes the first-in-human LANTERN Phase 1b/2a trial, testing ZAG-101 in adults with Stage 3 T1D. - FinancialContent
What's notable is how the trial is wired: beyond safety and pharmacology, it tracks C-peptide (a measure of your own insulin production) alongside immune assays for regulatory and effector T-cell responses. That is the same regulatory-versus-effector balance the IL-2 approach is trying to shift.
"Advancing ZAG-101 into the clinic marks Zag's transition to a clinical stage company," said Jason Cole, Chief Executive Officer of Zag Bio.
Initial enrollment is planned in Australia and Europe, with later expansion to adolescents and earlier disease stages.
Researchers find stem-like immune cells that may help type 1 diabetes persist reports an enrichment of "stem-cell-memory-like" CD8 T cells in pancreatic lymph nodes of people with T1D. - Diabetes.co.uk
This is the kind of basic science that could explain why the autoimmune attack drags on for years: a self-renewing reservoir of T cells that keeps generating fresh attackers. The authors point to IL-15 signalling as a possible driver, but they're candid about the limits.
This is mechanistic human-tissue research, not evidence that a new treatment is ready for patients.
Still, mapping where and how these cells persist is exactly how you design smarter immunotherapies down the line.
🩺 Screening and other news worth your time
Immunotherapy only helps if you can catch disease early enough to use it. That makes the screening news this week relevant.
Massive Eight-Country Trial Shows Childhood Type 1 Diabetes Screening Works reports that the EDENT1FI consortium screened 140,568 children across eight European countries using one harmonised protocol. Most detected cases were earliest-stage (78% stage 1, 18% stage 2, 4.1% stage 3), and most occurred in children with no family history, which underscores why population-wide screening matters. - Scienmag
Scientists Skip DNA Extraction to Score Type 1 Diabetes Risk Straight From Serum describes a proof-of-principle method to compute a ten-SNP genetic risk score directly from serum, potentially letting labs combine antibody and genetic testing from a single tube. The catch is sample handling: serum clotted 30 minutes or less had just 68.8% genotyping success. - Scienmag
In Brief: A New Indication for Finerenone (Kerendia) covers the FDA's approval of finerenone to reduce the urinary albumin-to-creatinine ratio in adults with chronic kidney disease linked to T1D, based on the FINE-ONE trial in 242 adults (34% vs 12% UACR reduction over 6 months). The main safety flag is hyperkalemia. - The Medical Letter
Dual-hormone fully closed-loop therapy versus multiple daily insulin injections or hybrid closed-loop therapy in adults with type 1 diabetes found that a dual-hormone fully closed-loop system raised time-in-range versus injections plus CGM (8.3%; P=0.03) but not versus a hybrid closed-loop (P=0.80), with more severe hypoglycemia (9 vs 2 events) and 50% discontinuation. A useful reality check on device burden. - The Lancet Regional Health - Europe
vTv Fully Enrolls Phase 3 Cadisegliatin Trial in Type 1 Diabetes reports completed enrollment (166 patients) in CATT1, testing the oral drug cadisegliatin as an insulin add-on aimed at cutting clinically significant hypoglycemia. Topline results are expected mid-2027; it's not FDA approved. - PRISM MarketView
📅 One to mark down
Breakthrough T1D to Host Inaugural Type 1 Diabetes Clinical & Research Congress announces CRC 2026, running October 9-11, 2026, in Philadelphia, with more than 80 scientific sessions spanning immunotherapies, disease-modifying therapies, early-stage screening, and access gaps. - Breakthrough T1D
Given everything above, the framing from their CEO lands well:
"Scientific advances only make a difference when they can improve someone's care."
That is the right lens for all of this immune research: the measure isn't how clever the biology is, but whether it reaches the people living with T1D. Take care of yourselves, and we'll see you next issue.